Takeda's Dengue Vaccine Candidate Aims To Avoid Dengvaxia Problems
TAK-003 is designed to be effective in those never exposed to dengue; Takeda expects Phase III results by end of 2018.
You may also be interested in...
Takeda continues to pursue the transformation of its R&D activities, which has already led to expansion of the pipeline, but will continue with core strategies including partnering even after the huge Shire acquisition.
From 'breakthrough' designations to manufacturing hiccups, numerous review and development challenges await the combined entity.
WHO’s recommendation around a pre-vaccination screening strategy for Sanofi’s Dengvaxia could potentially dull the prospects of the product further, especially in emerging markets with stretched healthcare resources. One industry expert suggests that governments should probably consider introducing the vaccine only after “better tests and tools” become available.